REGISTER TODAY to view the live stream!
Start Date:11/10/2022
Start Time: 8:30-12:30 ET
Abstract:
Vaxxinity is hosting an Analyst and R&D Day with a live webcast. Vaxxinity’s directors and management, and subject matter experts in neuroscience, migraine and hypercholesterolemia will discuss development candidates from the company’s synthetic peptide vaccine pipeline. The meeting will be held on Thursday, November 10, 2022 from 8:30 a.m. to 12:30 p.m. ET in New York City.
If you're already registered for the Vaxxinity Analyst and R&D Day webcast, click below:
ALREADY REGISTERED?
Speakers
Brian Fiske, PhD Co-Chief Scientific Officer The Michael J. Fox Foundation for Parkinson’s Research Brian joined the Michael J. Fox Foundation for Parkinson's Research in 2004. As Chief Scientific Officer, Brian works with a team of professionals who stay closely linked to the Parkinson's community in order to develop an aggressive and innovative strategic vision for accelerating research and drug development for Parkinson's disease. This ensures that MJFF priorities reflect and best serve the ultimate needs of patients.
Dr. Fiske earned an undergraduate degree in biology from Texas A&M University and a PhD in Neuroscience from the University of Virginia. After completing postdoctoral research at Columbia University, Brian spent several years as an editor for the scientific journal, Nature Neuroscience, before coming to the Foundation to help bring new treatments to people with Parkinson's.
Brian is passionate about the mission of the Foundation. In addition to his work as a Foundation scientist, Brian has been an active Team Fox member, running the New York Marathon and other race event to raise critical funds for research.
Dr. Jeffrey L. Cummings, ScD Vice Chair of Research University of Nevada Las Vegas Department of Brain Health Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health
Sciences in 2019 as research professor within the department of brain health. Dr.
Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed
professorship. He is the Director of the Chambers-Grundy Center for
Transformative Neuroscience, a center devoted to using the tools of neuroscience
and neurologic drug development to transform people’s lives.
Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic
Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S.
Easton Center for Alzheimer’s Disease Research, and director of the Deane F.
Johnson Center for Neurotherapeutics, both at UCLA.
A world-renowned Alzheimer’s researcher and leader of clinical trials, Dr.
Cummings has been recognized for his scientific and leadership contributions with
the American Geriatrics Society’s Henderson Award (2006), the national
Alzheimer’s Association’s Ronald and Nancy Reagan Research Award (2008), and
the American Association of Geriatric Psychiatry’s Distinguished Scientist Award
(2010).
Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain
diseases, and the interface of neuroscience and society. Dr. Cummings has
published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer’s
disease, and clinical trials.
Dr. Cummings received the Society for Behavioral and Cognitive Neurology’s
Lifetime Achievement Award (2017), the International Society of CNS Drug
Development’s Leadership and Achievement Award and the national Alzheimer’s
Association’s Bengt Winblad Lifetime Achievement Award (2018).
Additionally, he was featured in Gentleman’s Quarterly (June 2009) as a “Rock
Star of Science. ™” In addition to his work at UNLV, Dr. Cummings is professor of
medicine (Neurology) at Cleveland Clinic Lerner College of Medicine at Case
Western Reserve University, and he is principal investigator/director of the
National Institute of General Medical Sciences-funded Center for
Neurodegeneration and Translational Neuroscience.
Dr. Rob Scott Former Chief Medical Officer at AbbVie and VP Global Development, Therapeutic Area Head at Amgen Dr Rob Scott is a Zimbabwean born physician and a graduate of University of Cape
Town. Rob has held leadership positions in global Pharma for over thirty years. At Pfizer
he developed Lipitor and Norvasc. He invented and developed the first commercially
available Polypill - Caduet. At AtheroGenics, he conducted the first large cardiovascular
outcomes study to be wholly performed by a small biotech. At Amgen, Rob accelerated
and achieved first approval for a PCSK9i, Repatha. Rob was also successful in getting
FDA approval for the heart failure drug, Corlanor, despite not having a single US subject
in testing. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee
from 2012 to 2016 and participated as a committee member fourteen times. Rob retired
in 2020 as the Chief Medical Officer at Abbvie where he had responsibility for around 40
new molecular entities, four thousand people and a budget of close to two billion
dollars. During his tenure, Abbvie achieved over 14 major regulatory approvals including
Venclexta, Orilissa, Skyrizi and Rinvoq. He also created the Development Design
Center, a Center of Excellence focused on using predictive analytics and big data to
design and implement better clinical trials. He has been a board member of
Transcelerate and the PhRMA R&D Leadership Forum. Rob is a leader in digital
transformation of clinical research including a broad range of aspects from predictive
analytics, innovative program and study design, synthetic and historical controls,
pragmatic and real world studies, use of passive data collection using IoT and
wearables and risk based monitoring to name a few. Rob is currently on the board of
ArisGlobal, Confo Therapeutics, Draupnir Bio, Oncospherix, WindTree Therapeutics,
Redx Pharma and Variant Bio. He is also on the scientific and strategic advisory boards
of Variant Bio, Morningside Biopharma, Cytel, Inflexion, Orange Grove Bio and
BioEthics International. Rob is a founding member of WSW LLC, an investment fund
that is a limited partner of Frazier Healthcare
Dr. Stephen Silberstein Professor, Director Jefferson Headache Center Stephen D Silberstein, MD, is a Professor of Neurology and the Director of the
Jefferson Headache Center at Thomas Jefferson University. He is a Fellow of the
American College of Physicians, the American Academy of Neurology, and the
American Headache Society. He has served the American Headache Society as
President, Treasurer, and Board of Directors member. In 2016, he was awarded a
Lifetime Achievement Award by the American Headache Society. Dr Silberstein is
an active member of the American Academy of Neurology and is Co-director of the
national and international Headache Guideline Project, in cooperation with the
Agency for Health Care Policy and Research. He was the Chairman of the
International Headache Society meeting in Philadelphia in 2009. He is Chairman
of the headache research group of the World Federation of Neurology.
Dr Silberstein received his medical degree from the University of Pennsylvania.
After completing a fellowship in neurology at the National Hospital for Nervous
Diseases in London, he served as a Pharmacology Research Associate in the
Toxicology Laboratory of Clinical Science at the National Institutes of Mental
Health and completed a neurology residency at the Hospital of the University of
Pennsylvania.
Dr Silberstein is the Senior Editor of the 8th edition of Wolff's Headache and Other
Head Pain, Associate Editor of Cephalalgia and CNSDrugs, and a present or prior
member of the Editorial Board of Headache; Cephalalgia; Acta Neurologica
Scandinavica; Journal of Neurology, Neurosurgery & Psychiatry; and Topics in
Pain Management. He is an ad hoc reviewer for many publications, including The
New England Journal of Medicine; Brain, The Lancet, JAMA, Mayo Clinic
Proceedings, Annals of Neurology and Neurology.
Dr Silberstein has more than 300 publications to his credit. He lectures extensively
on the pathogenesis, neurobiology, diagnosis and treatment of headache.
|
Vaxxinity Analyst and R&D Day
Registration Is Closed
|
|
|